The Tumor Microenvironment Challenge for Cancer Treatment
IMMUNO-ONCOLGY REVOLUTIONIZED AND BROUGHT HIGH HOPES IN CANCER CURE.
CANCER CELLS ARE HYPERGLYCOLYTIC (WARBURG EFFECT) CREATING A MODIFIED TUMOR MICROENVIRONMENT AND RIGIDITY WHICH ARE DEFAVORABLE TO IMMUNO-ONCOLOGY DRUGS.
THE HK2 GLYCOLYTIC ENZYME OVER EXPRESSED IN CANCER CELLS BINDS TO VDAC CHANNEL ON MITOCHONDRIA BLOCKING APOPTOSIS & FAVORIZING CELL GROWTH
THROUGH MODIFICATION OF THE TUMOR MICROENVIRONMENT BY DETACHING MISLOCATED HK2 WITHOUT AFFECTING NORMAL GLYCOLYSIS VIDAC PHARMA NEW CHEMICAL ENTITIES:
DIRECTLY TREAT CANCER CELLS WITHOUT AFFECTING NORMAL ONES
IS THE SOLUTION FOR CLEARING THE WAY TO IMMUNO-ONCOLOGY REVOLUTION
